Overview

Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study investigates the common features of electrophysiological measures in schizophrenia and effects of NMDA antagonist ketamine in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
AstraZeneca
Treatments:
Ketamine